BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 17509426)

  • 1. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention.
    Seyon RA; Jensen LA; Ferguson IA; Williams RG
    Heart Lung; 2007; 36(3):195-204. PubMed ID: 17509426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature.
    Goldenberg I; Shechter M; Matetzky S; Jonas M; Adam M; Pres H; Elian D; Agranat O; Schwammenthal E; Guetta V
    Eur Heart J; 2004 Feb; 25(3):212-8. PubMed ID: 14972421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.
    Thiele H; Hildebrand L; Schirdewahn C; Eitel I; Adams V; Fuernau G; Erbs S; Linke A; Diederich KW; Nowak M; Desch S; Gutberlet M; Schuler G
    J Am Coll Cardiol; 2010 May; 55(20):2201-9. PubMed ID: 20466200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
    Toso A; Maioli M; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Manzone C; Amato M; Bellandi F
    Am J Cardiol; 2010 Feb; 105(3):288-92. PubMed ID: 20102936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetylcysteine and sodium bicarbonate versus N-acetylcysteine and standard hydration for the prevention of radiocontrast-induced nephropathy following coronary angiography.
    Schmidt P; Pang D; Nykamp D; Knowlton G; Jia H
    Ann Pharmacother; 2007 Jan; 41(1):46-50. PubMed ID: 17190844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
    Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial.
    Majumdar SR; Kjellstrand CM; Tymchak WJ; Hervas-Malo M; Taylor DA; Teo KK
    Am J Kidney Dis; 2009 Oct; 54(4):602-9. PubMed ID: 19535188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
    Ochoa A; Pellizzon G; Addala S; Grines C; Isayenko Y; Boura J; Rempinski D; O'Neill W; Kahn J
    J Interv Cardiol; 2004 Jun; 17(3):159-65. PubMed ID: 15209578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography.
    MacNeill BD; Harding SA; Bazari H; Patton KK; Colon-Hernadez P; DeJoseph D; Jang IK
    Catheter Cardiovasc Interv; 2003 Dec; 60(4):458-61. PubMed ID: 14624421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reno-protective effect of N-acetyl cysteine in patients with impaired renal function undergoing coronary angiography and interventions.
    Ramesh N; Pillai RK; Abraham T; Padmaja NP; Hameed S; Vijayaraghavan G
    J Assoc Physicians India; 2006 Jun; 54():449-52. PubMed ID: 16909692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
    Maioli M; Toso A; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Bellandi F
    J Am Coll Cardiol; 2008 Aug; 52(8):599-604. PubMed ID: 18702961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathophysiology and prevention of contrast-induced acute renal failure].
    Graziani G; Degnoni V; Oldani S; Buskermolen M; Brambilla G
    G Ital Nefrol; 2007; 24 Suppl 38():20-4. PubMed ID: 17922443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
    Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study.
    Ferrario F; Barone MT; Landoni G; Genderini A; Heidemperger M; Trezzi M; Piccaluga E; Danna P; Scorza D
    Nephrol Dial Transplant; 2009 Oct; 24(10):3103-7. PubMed ID: 19549691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy.
    Baskurt M; Okcun B; Abaci O; Dogan GM; Kilickesmez K; Ozkan AA; Ersanli M; Gurmen T
    Eur J Clin Invest; 2009 Sep; 39(9):793-9. PubMed ID: 19500141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.
    Coyle LC; Rodriguez A; Jeschke RE; Simon-Lee A; Abbott KC; Taylor AJ
    Am Heart J; 2006 May; 151(5):1032.e9-12. PubMed ID: 16644332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial.
    Ozcan EE; Guneri S; Akdeniz B; Akyildiz IZ; Senaslan O; Baris N; Aslan O; Badak O
    Am Heart J; 2007 Sep; 154(3):539-44. PubMed ID: 17719303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention.
    Spargias K; Alexopoulos E; Kyrzopoulos S; Iokovis P; Greenwood DC; Manginas A; Voudris V; Pavlides G; Buller CE; Kremastinos D; Cokkinos DV
    Circulation; 2004 Nov; 110(18):2837-42. PubMed ID: 15492300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.